up and coming crypto currencies Featured

Yuanyuan Communication: The plan being evaluated and negotiated between the company and toy manufacturers does not involve ByteDance, and the results of subsequent negotiations are still uncertain.Eight-day four-board three-dimensional communication: the company's operation is normal, and the internal and external operating environment has not changed significantly. On December 9, December 10 and December 11, 2024, the company's closing price increase deviated by more than 20% for three consecutive trading days, which belongs to the abnormal fluctuation of stock trading. The company's operation is normal, and the internal and external operating environment has not changed significantly. The Company has no other circumstances that violate the provisions on fair disclosure of information.Guohai Securities gave Youyou Food Co., Ltd. the initial rating of buying.

The General Administration of Market Supervision held an anti-monopoly compliance lecture hall for the automobile industry. On December 11th, the General Administration of Market Supervision held the ninth anti-monopoly compliance lecture hall in Beijing to give lectures on anti-monopoly compliance for the automobile industry. The General Administration of Market Supervision requires the business entities of the automobile industry to compact the responsibility of the anti-monopoly compliance subject, actively regulate business practices, establish and improve the anti-monopoly compliance system, and effectively prevent and stop the occurrence of monopoly behaviors. The General Administration of Market Supervision will continue to pay attention to the competition in the automobile industry, further promote the special anti-monopoly law enforcement actions in the field of people's livelihood, promote the formation of a fairer and more dynamic market environment, and continuously enhance the people's sense of acquisition, happiness and security. (City speaks Newspeak)The onshore RMB against the US dollar officially closed at 7.2590 at 16:30 Beijing time, down 97 points from the official closing price of the previous trading day and down 99 points from the closing price of the previous day and night.Liaoning Energy: Guo Hongbo, the chairman of the board of directors, resigned due to job change. Liaoning Energy (600758) announced on the evening of December 11th that Guo Hongbo applied to resign as the chairman, director and all the special committees under the board of directors due to job change. After resigning, Guo Hongbo no longer holds any position in the company.

Japanese manufacturers' confidence index turned negative to the central bank's forecast in December. A short-term survey in Reuters, Japan, found that Japanese manufacturers' business confidence deteriorated further in December due to concerns about US protectionist policies. The survey of 505 large Japanese non-financial enterprises showed that manufacturers' confidence index fell from 5 in November to -1 in December, which was the first time since last February, and the number of pessimists exceeded optimists for the first time in 10 months. The loss of business confidence may cast a shadow over the Bank of Japan's forecast. The Bank of Japan had previously predicted that a steady recovery driven by rising wages and consumption would help inflation reach the 2% target in a sustainable way and justify further interest rate hikes. Many manufacturing industries have reported that business confidence has declined. Among electronic machinery manufacturers, steel and non-ferrous metal manufacturers, pessimists far exceed optimists.Tomato Fiction: In the coming year, 200 million yuan will be invested to support fine content. On December 11th, at the Tomato Fiction Creators' Conference, Tomato Fiction announced that it will invest 200 million yuan in cash to support fine content in 2025, and continue to launch a series of support plans to make efforts in IP ecology. In 2024, tomato novels launched more than 10 support programs, and a total of 120 million yuan of extra bonuses were distributed.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.